Clinical experience of weekly paclitaxei-based treatment as preoperative chemotherapy for patients with primary breast cancer

Breast Cancer

Volumn 11, Issue 2, 2004, Pages 187-193

  Watatani, Masahiro ^a   Ueda, Kazuki ^a   Daito, Koji ^a   Azumi, Tatsuya ^a   Hirai, Teruhiko ^a   Yamato, Munehisa ^a   Hojo, Toshiya ^a   Hirai, Kyoko ^a   Inui, Hiroki ^a   Shiozaki, Hitoshi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Paclitaxel; Preoperative chemotherapy; Weekly administration

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL;

ADJUVANT THERAPY; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NEUTROPENIA; SEGMENTAL MASTECTOMY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; PACLITAXEL; TREATMENT OUTCOME;

EID: 16544384404     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02968300     Document Type: Article

References (22)

1. Hortobagyi GN, Singletary SE, Strom EA: Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK eds, Disease of the breast, 2nd ed, Lippincott Williams & Wilkins, Philadelphia, pp645-660, 2000.
2. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Yoldi GC, Zucali R, Rilke F, Andreola S, Silvestrini R, Fronzo G, Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-1545, 1990. (Pubitemid 20296503)
3. Morrow M, Harris JR: Local management of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK eds, Disease of the breast, 2nd ed, Lippincott Williams & Wilkins, Philadelphia, pp515-560, 2000.
4. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-2493, 1997. (Pubitemid 27289876)
5. Hage JA, Velde CJH, Julien JP, Tubiana-Hulin M, vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19:4224-4237, 2001. (Pubitemid 33081640)
6. Kaufmann M, Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volta T, Senn HJ: International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: Review and recommendations. J Clin Onco121:2600-2608, 2003. (Pubitemid 46606344)
7. Brain E, Garrino G, Misset JL, Carbonero IG, Itzhaki M, Cvitkovic E, Goldschmidt E, Burki F, Regensberg C, Pappo E, Hagipantelli R, Musset M: Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracyclinebased neoadjuvant chemotherapy. Br J Cancer 75:1360-1367, 1997. (Pubitemid 27179829)
8. Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, Sacks N, McKinna J: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.J Clin Oncol 16:107-114, 1998. (Pubitemid 28041586)
9. Buzdar AU, Singletary SE, Thefiault RL, Booser D J, Valero V, Ibrahim N, Smith T1, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN: Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable cancer. J Clin Onco117:3412-3417, 1999. (Pubitemid 29517908)
10. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Multicenter, randomized comparative study of two dose of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996. (Pubitemid 26185461)
11. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over. J Clin Onco118:724-733, 2000. (Pubitemid 30106602)
12. Ito Y, Hofikoshi N, Watanabe T, Sasaki Y, Tominaga T, Okawa T, Tabei T, Kuraishi Y, Tamura K, Abe R, Kitajima M, Yamaguchi S, Kobayashi T, Koyama H, Ofita K, Takashima S, Nomura Y, Ogawa M: Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. Invest. BMS-181339 breast cancer study group. Invest New Drugs 16:183-190, 1998. (Pubitemid 28495222)
13. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R: Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223, 2001. (Pubitemid 33081639)
14. Japanese Breast Cancer Society General rules for clinical and pathological recording of breast cancer. 14th ed, Kanehara Shuppan, Tokyo pp69-72, 2000 (in Japanese).
15. Hayward JL, Carbone pp, Heuson JC, Kumaoka S, Segaloff A: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35:292-298, 1977.
16. Buzdar AU, Singletary E, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, berry D, Hortobagyi GN: Evaluation of paclitaxel in adjuvant chemotherapy fro patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res 8:1073-1079, 2002. (Pubitemid 34517642)
17. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales M, Cfistofanilli M, Booser D J, Pusztai L, Rivera E, Thefiault R, Carter C, Singletary SE, Kuerer HM, Hunt K, Strom E, Hortobagyi GN: Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission rates when compared to every 3-week paclitaxel therapy followed by FAC-final results of a prospective phase Ill randomized trial. Proc Am Soc Clin Onco121:35a, 2002.
18. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, Decillis A, Robidoux A, Margolese RG, Cruz AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998. (Pubitemid 28363030)
19. O'Leary J, Volm M, Wasserheit C, Muggia F: Taxanes in adjuvant and neoadjuvant therapies for breast cancer. Oncology 12:23-27, 1998. (Pubitemid 28113735)
20. Rouzier R, Extra JM, Klijanienko J, Falcou MC, Asselain B, Salomon AV, Vielh P, Bourstyn E: Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to 2"3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Onco120:1304-1310, 2002. (Pubitemid 34177437)
21. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant breast and Bowel Project B-18. J Natl Cancer lnst Monogr 30:69-102, 2001.
22. Rouzier R, Extra JM, Carton M, Falcou MC, Salomon AV, Fourquet A, Pouillart P, Bourstyn E: Primary chemotherapy for operable breast cancer: Incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19:3828-3835, 2001. (Pubitemid 32880061)